NCT06064682 An Organoid-based Functional Precision Medicine Trial in Osteosarcoma
| NCT ID | NCT06064682 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Jonsson Comprehensive Cancer Center |
| Condition | Osteosarcoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2024-02-12 |
| Primary Completion | 2027-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 40 participants in total. It began in 2024-02-12 with a primary completion date of 2027-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to examine if we can predict sensitivity of osteosarcoma to different chemotherapy agents using tissue cultures in the laboratory. We know that different chemotherapy agents can be used in the treatment, but not every sarcoma responds to them equally. It is important to understand if testing of the tissue obtained during a routine biopsy or surgery may be useful in selecting appropriate treatments. In addition, additional testing of the tumor, including genetic testing, will help us to understand osteosarcoma better.
Eligibility Criteria
Inclusion / exclusion criteria - Group1: \- Patients without diagnosis of osteosarcoma and whose imaging studies are suggestive of osteosarcoma and who are planned to undergo biopsy or surgery for diagnostic purposes Inclusion / exclusion criteria - Group 2: \- Patients whose imaging studies are suggestive of metastatic osteosarcoma and who are planned to undergo biopsy or surgery for diagnostic purposes
Contact & Investigator
Alice Soragni, PhD
PRINCIPAL INVESTIGATOR
University of California at Los Angeles
Frequently Asked Questions
Who can join the NCT06064682 clinical trial?
This trial is open to participants of all sexes, studying Osteosarcoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06064682 currently recruiting?
Yes, NCT06064682 is actively recruiting participants. Contact the research team at SSwearingen@mednet.ucla.edu for enrollment information.
Where is the NCT06064682 trial being conducted?
This trial is being conducted at Los Angeles, United States.
Who is sponsoring the NCT06064682 clinical trial?
NCT06064682 is sponsored by Jonsson Comprehensive Cancer Center. The principal investigator is Alice Soragni, PhD at University of California at Los Angeles. The trial plans to enroll 40 participants.